Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

Facility releasing air pollution|google, for article on China sulphur dioxide reduction

China has reduced sulphur dioxide emissions by more than two-thirds in the last 15 years

By / / Good News For Humankind

China’s sulphur dioxide emissions fell by 70 percent between 2006 and 2017, even as the country’s economy roughly tripled in size over the same stretch. That kind of decoupling — slashing a major industrial pollutant while growing fast — is something climate scientists have long argued was possible but rarely seen at this scale. The shift came from real policy muscle: stricter enforcement, legal accountability for local officials, and a massive pivot to clean energy, with China funding nearly half of global renewable investment in 2017 alone. Coal still looms large and the work is far from done, but this milestone is tangible proof that entrenched pollution problems can move, and quickly, when commitment meets follow-through.

Depiction of intestines, for article on dostarlimab FDA breakthrough designation, for article on dostarlimab FDA Breakthrough Designation

“100% successful” cancer drug gets landmark U.S. FDA approval

By / / Good News For Humankind

A cancer drug called dostarlimab just earned the FDA’s Breakthrough Therapy Designation after eliminating rectal tumors in all 42 patients who completed a Memorial Sloan Kettering trial — with some participants now cancer-free for up to four years. The drug works by helping the immune system recognize and attack tumors carrying a specific genetic signature, sparing patients the surgery, radiation, and chemotherapy that often leave lasting damage to fertility, bowel function, and quality of life. Side effects have been mild, and the new designation could shave years off the path to wider availability. For the roughly 46,220 Americans diagnosed with rectal cancer each year, this hints at a future where beating the disease no longer means trading one kind of suffering for another.

Medical researcher in a lab examining vials related to asthma and COPD treatment and mRNA vaccine development, for article on benralizumab injection, for article on mRNA lung cancer vaccine

Injection beats steroids for asthma and COPD attacks in first major advance in 50 years

By / / Good News For Humankind

Asthma and COPD treatment may be on the verge of its biggest advance in 50 years, after a clinical trial found that a single injection of benralizumab outperformed standard steroid tablets for treating acute attacks. The study, published in Lancet Respiratory Medicine, showed four times fewer treatment failures at three months and 30% fewer follow-up interventions among patients receiving the injection. The trial targeted eosinophilic flare-ups, the biological subtype behind roughly half of all asthma attacks and nearly a third of COPD episodes. Together, the two conditions kill an estimated 3.8 million people annually, yet the standard of care has remained largely unchanged since the 1970s.

Breakthrough genomic test identifies virtually any infection in one go

By / / Good News For Humankind

A single lab test can now identify almost any pathogen — bacteria, virus, fungus, or parasite — from one patient sample, and it correctly pinpointed 86% of neurological infections in a trial of nearly 5,000 patients at UC San Francisco. The method, called metagenomic next-generation sequencing, screens cerebrospinal fluid against a library of more than 68,000 known pathogens and returns answers in about 48 hours, replacing weeks of educated guesswork with a clear picture of what’s actually there. An adapted version for respiratory samples could spot novel viral strains in 12 to 24 hours, offering an early warning system for future outbreaks. If deployed equitably, it could reshape how the world diagnoses infections and detects pandemics before they spread.

digitally colorized scanning electron microscopic (SEM) image, depicts a blue-colored, human white blood cell, (WBC) known specifically as a neutrophil, interacting with two pink-colored, rod shaped, multidrug-resistant (MDR), Klebsiella pneumoniae bacteria, for article on pneumococcal vaccine, for article on pneumococcal vaccines

Global child deaths from pneumonia have been cut in half since 2009

By / / Good News For Humankind

Childhood pneumonia deaths have been cut roughly in half since 2009, when a new kind of vaccine funding model launched and 438 million children across 64 countries received pneumococcal vaccines. The breakthrough wasn’t just the science — it was a $1.5 billion fund that guaranteed manufacturers a buyer, bringing prices down so lower-income countries could finally afford to protect their kids. In Kenya, invasive pneumococcal disease in young children dropped 92% within eight years of rollout. Now the vaccine is reaching fragile places like Chad, Somalia, and South Sudan, where a single dose can mean the difference between life and death. It’s a quiet reminder that when global health gets the funding right, millions of children grow up who otherwise wouldn’t.

Close-up of a human eye with clear cornea, for an article about stem-cell cornea transplant research in Japan, for article on stem-cell cornea transplant

Japanese researchers restore sight with stem-cell cornea transplants in a world first

By / / Good News For Humankind

Stem-cell cornea transplants have been successfully performed on human patients for the first time, with Japanese surgeons using reprogrammed induced pluripotent stem cells to restore vision in three of four participants — results that held for more than a year. Published in The Lancet in 2024, the trial offers a potential path around the global shortage of donor corneal tissue, which currently leaves millions without treatment options. Corneal disease is among the leading causes of blindness worldwide, making a scalable alternative to donor transplants significant. While the trial was small, a 75% sustained success rate in a first-in-human study is a meaningful early result.

A doctor is about to vaccinate a child, for article on malaria vaccine rollout

Sudan launches first malaria vaccine in landmark child health initiative

By / / Good News For Humankind

Sudan’s malaria vaccine rollout is reaching more than 148,000 children under 12 months in its opening phase, making it the first country in the WHO Eastern Mediterranean Region to launch the shot nationally. That’s remarkable on its own, but consider the backdrop: hospitals shuttered, health workers unpaid for months, and a war reshaping daily life. Even so, the Federal Ministry of Health worked with UNICEF, WHO, and Gavi to train staff, build cold chain capacity, and reach two states, with expansion to 129 localities planned by 2026. It’s a quiet reminder that even in the hardest places, public health progress can still find a way through.

Blood cells under microscope, for article on smart insulin

Danish scientists design new form of insulin that automatically switches itself on and off

By / / Good News For Humankind

Smart insulin that reads blood sugar in real time and adjusts its own activity has cleared a major hurdle in animal trials, according to Danish researchers publishing in Nature. The molecule switches on when glucose climbs and powers down as levels normalize, mimicking the feedback loop of a healthy pancreas. That matters because conventional insulin can overshoot and trigger dangerously low blood sugar, a side effect that endangers people living with diabetes every day. Scientists have chased this idea for more than 40 years, and earlier candidates kept stumbling in living bodies. For the more than 500 million people worldwide managing diabetes, an insulin that doses itself would be a quiet revolution — bringing daily care closer to how the body was meant to work.

Insulin pens, for article on duodenal mucosal resurfacing

New treatment eliminates insulin for 86% of patients in early trials

By / / Good News For Humankind

A one-hour outpatient procedure helped 12 of 14 Type 2 diabetes patients stop using insulin entirely and stay off it for a full year. Researchers at Amsterdam University Medical Center used a catheter to deliver gentle electrical pulses to the lining of the small intestine, prompting the tissue to regenerate and apparently restoring the body’s natural insulin response. By comparison, the widely used medication semaglutide alone helps only about one in five patients discontinue insulin. The team calls the approach “disease-modifying” because it targets the root cause rather than the symptoms, and a larger randomized trial is now in the works. If the results hold, it could reshape how a condition affecting hundreds of millions worldwide is treated.

Ovarian and Cervical Cancer Awareness. a Teal Ribbon, for article on cervical cancer treatment

New cervical cancer treatment regime ‘cuts risk of dying from disease by 40%’

By / / Good News For Humankind

Cervical cancer treatment just took its biggest leap in 25 years, and the breakthrough comes from a surprisingly simple idea: changing the timing. In a trial spanning the U.K., Mexico, India, Italy, and Brazil, women who received a short course of chemotherapy before standard chemoradiation were 40% less likely to die from the disease. Even better, the drugs involved are already approved, affordable, and widely available — meaning hospitals could adopt this approach without waiting on a new wonder drug. For the hundreds of thousands of women diagnosed each year, especially in lower-income countries where cervical cancer hits hardest, it’s a rare kind of medical good news: a major gain that’s actually within reach.